Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies
about
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Epirubicin and docetaxel as ne ...... wo successive phase II studies
@ast
Epirubicin and docetaxel as ne ...... wo successive phase II studies
@en
type
label
Epirubicin and docetaxel as ne ...... wo successive phase II studies
@ast
Epirubicin and docetaxel as ne ...... wo successive phase II studies
@en
prefLabel
Epirubicin and docetaxel as ne ...... wo successive phase II studies
@ast
Epirubicin and docetaxel as ne ...... wo successive phase II studies
@en
P2093
P2860
P356
P1476
Epirubicin and docetaxel as ne ...... wo successive phase II studies
@en
P2093
Alessandro Tuzi
Andrea Veronesi
Davide Lombardi
Diana Crivellari
Loredana Militello
Manuela La Grassa
Samuele Massarut
Tiziana Perin
P2860
P356
10.2478/RAON-2013-0012
P577
2013-02-01T00:00:00Z